Foghorn Therapeutics and Eli Lilly end FHD-909 and SMARCA2 collaboration; Foghorn to cut 40% of staff

Foghorn Therapeutics said it and Eli Lilly will not advance the FHD-909 program further and will also not advance the Selective SMARCA2 degrader program, with no further collaboration activities anticipated. Foghorn is cutting about 40% of its workforce; shares fell about 44% premarket.

Detected & updated continuously · Source: Nebula